



1623

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/587,662	
	Filing Date	June 5, 2000	
	First Named Inventor	Jessie L.-S. Au	
	Group Art Unit	1623	
	Examiner Name	Ganapathy Krishnan	
Total Number of Pages in This Submission	7	Attorney Docket Number	TNI 2-006

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Copies of Revocation of Power of Attorney	

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Jerry K. Mueller, Jr. Mueller and Smith, LPA
Signature	
Date	October 9, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: October 9, 2002			
Typed or printed name	Jane Keeney	Date	October 9, 2002
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: TNI 2-006

#8
10-22-02
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Jessie L.-S. Au, Ph.D., *et al.*)
Serial No. 09/587,662)
Filed: June 5, 2000)
For: METHODS AND COMPOSITIONS FOR)
MODULATING DRUG ACTIVITY)
THROUGH TELOMERE DAMAGE)

Examiner Ganapathy Krishnan
Group Art Unit 1623

RECEIVED

OCT 18 2002

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

Sir:

This paper is filed responsive to the Office action mailed September 9, 2002 (paper no. 7), which restricts the claims as follows:

Group I	Claims 1-28, 33-35, 40-48
Group II	Claims 29-31, 89
Group III	Claims 32, 36
Group IV	Claims 37-39
Group V	Claims 49-56
Group VI	Claims 57-88

Applicants respectfully elect the Group I claims, with traverse.

The Examiner further has issued a species election for the Group I claims, as follows:

Species A	paclitaxel as the telomere damage-inducing agent
Species B	nucleotide analog as the telomere damage-inducing agent

Applicants respectfully elect Species A, paclitaxel, with traverse.

The Species B group, nucleotide analog, is not a telomere damage-inducing agent, but rather is a telomerase inhibitory agent.

In even another embodiment, the telomere damage-inducing agent is paclitaxel, or a derivative thereof, and the telomerase inhibitory agent is a nucleotide analog, or derivative thereof, and in a preferred embodiment,

AZT or d4T. In a related embodiment, the telomerase inhibitory agent is an antisense nucleic acid corresponding to a telomerase.


Application at page 3, ll. 28-32

Thus, the species election appears to be improper. With the election of Species A, this error is moot.

Finally, it is noted that the outstanding Office action was not sent to the undersigned, despite a revocation/appointment of attorney form filed with the Office on April 23, 2002 (copy enclosed). Entry of the revocation/appointment of attorney form and recognition of the undersigned respectfully is requested.

Respectfully submitted,

Date: 9 October 02




Jerry K. Mueller, Jr.
Reg. No. 27,576
MUELLER AND SMITH, L.P.A.
MUELLER-SMITH BUILDING
7700 Rivers Edge Drive
Columbus, Ohio 43235-1355
Tel.: 614-436-0600
Fax: 614-436-0057
email: smueller@muellersmith.com

Enc.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited on October 9, 2002, with the United States Postal Service as first class mail in an envelope addressed to:

Box NON-FEE
Commissioner for Patents
Washington, D.C. 20231



Jane Keeney